Developer docs
API playgroundTry for free, no card

Search company profiles

CurePSP

Full company profile

uuid000c18t

Namestring
CurePSP
Legal namestring
CurePSP, Inc.
Websiteurl
psp.org
Company typeenum
Private
Founded yearint
1993
Descriptiontext

CurePSP, Inc. is a 501(c)(3) nonprofit organization founded in 1993 and headquartered at 325 Hudson Street, 4th Floor, New York. It is the leading U.S. patient-advocacy organization focused on three rare neurodegenerative tauopathies and synucleinopathies: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). The organization operates around three pillars — care, consciousness, and cure — and serves four primary segments: patients and care partners, healthcare professionals, researchers, and donors/supporters. It runs a network of 25 designated Centers of Care across the U.S. and Canada (established 2017) providing specialized clinical care, and partners with the Mayo Clinic Brain Bank, which houses over 2,000 PSP brains preserved over more than 30 years and shared with researchers nationally and internationally.

CurePSP's programmatic portfolio includes the Brain Donation Assistance Program (up to $1,000 in expense reimbursement via Mayo Clinic), the Quality of Life Respite Program (100 hours of professional in-home care at up to $40/hour, ~$4,000 grant value per family), the CARES grant program in its fourth year awarding $155,000 to four projects across seven institutions in 2026, and Pathway/Pipeline research grants of up to $100,000 for one- or two-year studies. Education and awareness channels include The Collective Mind podcast (Season 3 launching July 2026), CurePSPTV on YouTube, a resource library of downloadable booklets and audiobooks in multiple languages, and continuing-education partnerships with Shirley Ryan AbilityLab and the Parkinson's Foundation. The organization is led by CEO Kristophe Diaz, PhD.

CurePSP's business model is donation-driven rather than commercial. Revenue is generated through individual donations (processed via Convio), tribute gifts, fundraising events (e.g., Giving Tuesday), and a Shopify-hosted merchandise shop. It also accepts pharmaceutical industry contributions as unrestricted grants, activity sponsorships, or service compensation, disclosed under its Policy for Engaging with Industry. All programmatic services to patients and families are provided free of charge. Recent strategic activity includes co-organization of the Tau Global Conference 2026 with the Alzheimer's Association and Rainwater Charitable Foundation, a forthcoming Neuro2026 symposium with PSPA UK, and appointment of Director of Clinical Affairs Jessica Shurer to the inaugural National Parkinson's Project Advisory Council in April 2026.

Short descriptiontext

CurePSP is a 501(c)(3) nonprofit founded in 1993 that supports patients, families, and researchers affected by PSP, CBD, and MSA through a 25-center care network, a brain donation program tied to the Mayo Clinic Brain Bank, respite and research grants, and federal advocacy.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease advocacy, patient support services, medical research grants, rare disease awareness, caregiver respite programs
Industry2 codes
1Public–Private Partnerships (PPPs) for Global Health
CodeHLAJAOADPrimaryYes
2Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
CodeHLAJAOAMPrimaryNo
NAICS code3 codes
  • Voluntary Health Organizations813212
  • Services for the Elderly and Persons with Disabilities624120
  • Other Individual and Family Services624190
SIC code2 codes
  • Services-Social Services8300
  • Services-Misc Health & Allied Services, Nec8090
Product category
Neurodegenerative Disease Nonprofit Patient Advocacy
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Donations and Fundraising
TypeOthers
Description

CurePSP operates as a 501(c)(3) nonprofit organization funded primarily through donations from individuals, families, and supporters. The organization conducts fundraising campaigns including Giving Tuesday and general donation drives through its website and Convio platform.

psp.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1Quality of Life Respite Program Grant
ModelOtherBilling cadenceMulti-year contract
Notes

100 hours of professional, agency-based in-home care for people living with PSP, CBD or MSA. Cost covered up to $40/hour. Families with combined annual income under $90K and no long-term care insurance are eligible. Grant must start within 2 months of approval and used within 1 year. As of May 2026, families may reapply once they have exhausted the initial grant (limited to two per family).

psp.org
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 2 records shown
1Unlocking the Secrets of Brain Disease
Description

Registered trademark of CurePSP, Inc.

psp.org
+1 more record
Core offering1 text field

CurePSP is a 501(c)(3) nonprofit organization that raises awareness, funds research, and provides patient and family support services for three rare neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). Its core offerings include educational resources, the Quality of Life Respite Program, the Brain Donation Assistance Program, the Centers of Care Network, and research grant programs (CARES, Pathway, and Pipeline grants).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 25 designated Centers of Care providing specialized care for PSP, CBD, and MSA patients across U.S. and Canada
+3 more records
Product overview1 text field

CurePSP is a nonprofit organization offering a comprehensive suite of educational, supportive, and research-focused services for people affected by progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). The organization operates primarily as a disease-focused advocacy and support organization rather than a technology product company. Its offerings include: The Collective Mind Podcast and CurePSPTV for awareness and education; a Resource Library and Audiobook Library containing downloadable materials on disease management; the Brain Donation Assistance Program providing diagnostic services; the Quality of Life Respite Program offering in-home care grants; a Centers of Care Network of 25+ designated medical institutions; CARES Grants and Pathway/Pipeline Grants funding research and care initiatives; Healthcare Professional Resources including continuing education; and Assistive Devices directories. The organization connects these programs through its website at psp.org, serving patients, families, healthcare professionals, and researchers.

Product and service14 records
1Centers of Care Network
CategoryHealthcare Network
Description

Network of 25 designated medical institutions across the U.S. and Canada providing specialized clinical care for PSP, CBD, and MSA patients, established in 2017 with criteria centered on leadership in specialized therapies, comprehensive support services, and clinical research.

2CARES Grants (Collaborative Approaches to Resources, Education and Support)
CategoryGrant Program
Description

Grant program fostering partnerships within the Centers of Care network to address unmet care needs of the atypical Parkinsonism community, now in its fourth year with $155,000 awarded in 2026 across four projects at seven medical institutions in the U.S. and Canada.

3Pathway and Pipeline Grants
CategoryResearch Grant Program
Description

Research funding program providing grants of up to $100,000 for one- or two-year studies on PSP and CBD, with applications evaluated by CurePSP's Scientific Advisory Board.

4Brain Donation Assistance Program
CategorySupport Service
Description

Program providing up to $1,000 reimbursement for brain donation costs through the Mayo Clinic Brain Bank, enabling neuropathological diagnosis and supporting research into PSP, CBD, and MSA.

5Quality of Life Respite Program
CategorySupport Service
Description

Grant program providing 100 hours of professional, agency-based in-home care for people living with PSP, CBD or MSA, covering costs up to $40/hour. Families with combined annual income under $90K and no long-term care insurance are eligible.

6Support Groups
CategorySupport Service
Description

Peer support groups for patients and families affected by PSP, CBD, and MSA, providing emotional support, shared experiences, and community connection.

7Bereavement Resources
CategorySupport Service
Description

Resources and support materials for families who have lost loved ones to PSP, CBD, or MSA.

8Resource Library
CategoryEducational Resource
Description

Digital library of downloadable educational materials including booklets, fact sheets, workbooks, and guides for PSP, CBD, and MSA patients and families.

9Audiobook Library
CategoryEducational Resource
Description

Audiobook versions of CurePSP's Some Answers booklets providing accessible information on PSP, CBD, and MSA symptoms and management.

10Healthcare Professional Resources
CategoryEducational Resource
Description

Resources for physicians and healthcare professionals including continuing education programs, best practices guidelines, and diagnostic tools for PSP, CBD, and MSA, delivered in partnership with the Parkinson's Foundation and Shirley Ryan AbilityLab.

11Assistive Devices and Adaptive Equipment Directory
CategoryInformation Resource
Description

Curated list of assistive devices and adaptive equipment recommendations for patients and families dealing with PSP, CBD, and MSA symptoms.

12CurePSPTV (YouTube Channel)
CategoryContent/Awareness
Description

YouTube channel featuring educational and awareness video content about PSP, CBD, and MSA.

13The Collective Mind Podcast
CategoryContent/Awareness
Description

Podcast series featuring stories from care partners, advocates, physicians, scientists, researchers, and staff members discussing PSP, CBD, and MSA. Currently in Season 3 with monthly episodes released on Apple Podcasts, Spotify, Amazon Music, and iHeart.

14Annual Reports and Financial Statements
CategoryTransparency/Documentation
Description

Annual reports and audited financial statements documenting CurePSP's activities, finances, and impact.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1PSPA (UK)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-11-01
Description

Co-organizer of Neuro2026: The PSP and CBD International Research Symposium in London, bringing together the PSP and CBD research community with early clinical trial results expected.

psp.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Co-funding partnership for CARES grants supporting research and care initiatives for PSP, CBD, and MSA in Canada. Two projects are co-funded including research on barriers to diagnosis in underserved populations and evaluation of virtual wellness programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-14
Description

Co-organizer of Tau Global Conference 2026, bringing together approximately 400 in-person attendees and 800 virtual participants including researchers, clinicians, and people living with PSP, CBD and related tauopathies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-14
Description

Co-organizer of Tau Global Conference 2026 and provider of the Rainwater Prize honoring researchers at the Mayo Clinic Brain Bank. Partnership advancing tau research and awareness.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hosts CurePSP's Brain Bank with over 2,000 PSP brains of frozen and fixed tissue. Provides neuropathologic evaluation at no charge and generates diagnostic reports for families. Tissue is shared with researchers nationally and internationally.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership on Atypical Parkinsonism Podcast Series and online course 'Caring for Your Patients with Atypical Parkinsonism' providing continuing education credits for healthcare professionals.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership on on-demand webinar 'Rehabilitation Implications of Atypical Parkinsonisms' providing continuing education credits for physical therapists, occupational therapists, and speech-language pathologists.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Corporate supporter of the online course 'Caring for Your Patients with Atypical Parkinsonism' developed in partnership with Parkinson's Foundation.

9National Parkinson's Project Advisory Council
Strategic tierCoreTypeOthers
Description

Jessica Shurer, Director of Clinical Affairs and Advocacy at CurePSP, appointed to the inaugural National Parkinson's Project Advisory Council under the National Plan to End Parkinson's Act. Council will evaluate federal programs, advise HHS Secretary, and deliver recommendations on research priorities and care access strategies.

prnewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The largest U.S. voluntary health organization for dementia and a core co-organizer of the Tau Global Conference with CurePSP. Shares research funding mechanisms and federal advocacy, with overlapping interest in tau biology linking Alzheimer's and PSP/CBD.

TypeDirect peer
Description

National Parkinson advocacy and patient-support organization that co-publishes the Atypical Parkinsonism Podcast Series and the 'Caring for Your Patients with Atypical Parkinsonism' continuing-education course with CurePSP. Comparable in mission (care, education, research funding) and audience (Parkinson's and atypical parkinsonism patients and clinicians).

TypeDirect peer
Description

Major U.S. voluntary health organization focused on amyotrophic lateral sclerosis with the same three-pillar operating model (care, awareness, research funding) as CurePSP. Comparable scale, federal advocacy footprint, and Care Center network structure make it a structurally similar peer.

TypeDirect peer
Description

U.S. nonprofit focused on frontotemporal degeneration, an adjacent rare neurodegenerative disease with a similar patient-support, education, and research-funding operating model. Comparable in scale, structure, and disease-rare-advocacy positioning.

TypeDirect peer
Description

U.S. voluntary health organization for Lewy body dementia, another synucleinopathy adjacent to MSA with overlapping patient populations and a similar support, education, and research-advocacy mission.

6The Michael J. Fox Foundation for Parkinson's Research
TypeDirect peer
Description

The largest nonprofit funder of Parkinson's research, with a federal advocacy agenda that overlaps CurePSP's on the National Parkinson's Project Advisory Council. MJFF and CurePSP co-publish advocacy calls (e.g., the June 2026 advisory council coalition statement), making MJFF a direct peer in research funding, federal lobbying, and patient education.

TypeDirect peer
Description

Private foundation focused on tauopathy and neurodegenerative disease research that co-organizes the Tau Global Conference and funds the Rainwater Prize at the Mayo Clinic Brain Bank. Direct peer on CurePSP's most differentiated research asset.

TypeDirect peer
Description

Canadian national Parkinson advocacy organization that co-funds CurePSP's CARES grants for Canadian projects. Direct peer in cross-border atypical parkinsonism care and research funding.

TypeDirect peer
Description

The UK-based PSP and CBD patient organization and co-organizer of Neuro2026 with CurePSP. Operates the same disease-specific care, research funding, and awareness model outside North America.

TypeDirect peer
Description

National Parkinson's disease nonprofit providing patient services, professional education, and research grants, overlapping CurePSP on the federal Parkinson's advocacy coalition. Operates a comparable support-group and information-resource model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers15 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CurePSP

Neurodegenerative Disease Nonprofit Patient Advocacypsp.org

CurePSP is a 501(c)(3) nonprofit founded in 1993 that supports patients, families, and researchers affected by PSP, CBD, and MSA through a 25-center care network, a brain donation program tied to the Mayo Clinic Brain Bank, respite and research grants, and federal advocacy.

What CurePSP does

CurePSP, Inc. is a 501(c)(3) nonprofit organization founded in 1993 and headquartered at 325 Hudson Street, 4th Floor, New York. It is the leading U.S. patient-advocacy organization focused on three rare neurodegenerative tauopathies and synucleinopathies: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). The organization operates around three pillars — care, consciousness, and cure — and serves four primary segments: patients and care partners, healthcare professionals, researchers, and donors/supporters. It runs a network of 25 designated Centers of Care across the U.S. and Canada (established 2017) providing specialized clinical care, and partners with the Mayo Clinic Brain Bank, which houses over 2,000 PSP brains preserved over more than 30 years and shared with researchers nationally and internationally.

CurePSP's programmatic portfolio includes the Brain Donation Assistance Program (up to $1,000 in expense reimbursement via Mayo Clinic), the Quality of Life Respite Program (100 hours of professional in-home care at up to $40/hour, ~$4,000 grant value per family), the CARES grant program in its fourth year awarding $155,000 to four projects across seven institutions in 2026, and Pathway/Pipeline research grants of up to $100,000 for one- or two-year studies. Education and awareness channels include The Collective Mind podcast (Season 3 launching July 2026), CurePSPTV on YouTube, a resource library of downloadable booklets and audiobooks in multiple languages, and continuing-education partnerships with Shirley Ryan AbilityLab and the Parkinson's Foundation. The organization is led by CEO Kristophe Diaz, PhD.

CurePSP's business model is donation-driven rather than commercial. Revenue is generated through individual donations (processed via Convio), tribute gifts, fundraising events (e.g., Giving Tuesday), and a Shopify-hosted merchandise shop. It also accepts pharmaceutical industry contributions as unrestricted grants, activity sponsorships, or service compensation, disclosed under its Policy for Engaging with Industry. All programmatic services to patients and families are provided free of charge. Recent strategic activity includes co-organization of the Tau Global Conference 2026 with the Alzheimer's Association and Rainwater Charitable Foundation, a forthcoming Neuro2026 symposium with PSPA UK, and appointment of Director of Clinical Affairs Jessica Shurer to the inaugural National Parkinson's Project Advisory Council in April 2026.

CurePSP firmographics

Firmographics
Name
CurePSP
Legal name
CurePSP, Inc.
Website
https://psp.org
Company type
Private
Founded year
1993
Operating status
Operating
Short description
CurePSP is a 501(c)(3) nonprofit founded in 1993 that supports patients, families, and researchers affected by PSP, CBD, and MSA through a 25-center care network, a brain donation program tied to the Mayo Clinic Brain Bank, respite and research grants, and federal advocacy.
Ownership category
akta.pro rank

CurePSP industry classification

Industry
Product category
Neurodegenerative Disease Nonprofit Patient Advocacy
NAICS
Voluntary Health Organizations (813212), Services for the Elderly and Persons with Disabilities (624120), Other Individual and Family Services (624190)
SIC
Services-Social Services (8300), Services-Misc Health & Allied Services, Nec (8090)
akta.pro primary industry
Public–Private Partnerships (PPPs) for Global Health (HLAJAOAD)
akta.pro secondary industry
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

  • Neurodegenerative disease advocacy
  • Patient support services
  • Medical research grants
  • Rare disease awareness
  • Caregiver respite programs

Where CurePSP is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CurePSP business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Donations and Fundraising: CurePSP operates as a 501(c)(3) nonprofit organization funded primarily through donations from individuals, families, and supporters. The organization conducts fundraising campaigns including Giving Tuesday and general donation drives through its website and Convio platform.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuality of Life Respite Program Grant

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

CurePSP product offering

Product offering

Core offering

CurePSP is a 501(c)(3) nonprofit organization that raises awareness, funds research, and provides patient and family support services for three rare neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). Its core offerings include educational resources, the Quality of Life Respite Program, the Brain Donation Assistance Program, the Centers of Care Network, and research grant programs (CARES, Pathway, and Pipeline grants).

Product overview

CurePSP is a nonprofit organization offering a comprehensive suite of educational, supportive, and research-focused services for people affected by progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). The organization operates primarily as a disease-focused advocacy and support organization rather than a technology product company. Its offerings include: The Collective Mind Podcast and CurePSPTV for awareness and education; a Resource Library and Audiobook Library containing downloadable materials on disease management; the Brain Donation Assistance Program providing diagnostic services; the Quality of Life Respite Program offering in-home care grants; a Centers of Care Network of 25+ designated medical institutions; CARES Grants and Pathway/Pipeline Grants funding research and care initiatives; Healthcare Professional Resources including continuing education; and Assistive Devices directories. The organization connects these programs through its website at psp.org, serving patients, families, healthcare professionals, and researchers.

Differentiator

Problem solved

Functional benefit

Brands

  • Unlocking the Secrets of Brain Disease: Registered trademark of CurePSP, Inc.
  • Because Hope Matters

Products and services

  • Centers of Care Network Network of 25 designated medical institutions across the U.S. and Canada providing specialized clinical care for PSP, CBD, and MSA patients, established in 2017 with criteria centered on leadership in specialized therapies, comprehensive support services, and clinical research.
  • CARES Grants (Collaborative Approaches to Resources, Education and Support) Grant program fostering partnerships within the Centers of Care network to address unmet care needs of the atypical Parkinsonism community, now in its fourth year with $155,000 awarded in 2026 across four projects at seven medical institutions in the U.S. and Canada.
  • Pathway and Pipeline Grants Research funding program providing grants of up to $100,000 for one- or two-year studies on PSP and CBD, with applications evaluated by CurePSP's Scientific Advisory Board.
  • Brain Donation Assistance Program Program providing up to $1,000 reimbursement for brain donation costs through the Mayo Clinic Brain Bank, enabling neuropathological diagnosis and supporting research into PSP, CBD, and MSA.
  • Quality of Life Respite Program Grant program providing 100 hours of professional, agency-based in-home care for people living with PSP, CBD or MSA, covering costs up to $40/hour. Families with combined annual income under $90K and no long-term care insurance are eligible.
  • Support Groups Peer support groups for patients and families affected by PSP, CBD, and MSA, providing emotional support, shared experiences, and community connection.
  • Bereavement Resources Resources and support materials for families who have lost loved ones to PSP, CBD, or MSA.
  • Resource Library Digital library of downloadable educational materials including booklets, fact sheets, workbooks, and guides for PSP, CBD, and MSA patients and families.
  • Audiobook Library Audiobook versions of CurePSP's Some Answers booklets providing accessible information on PSP, CBD, and MSA symptoms and management.
  • Healthcare Professional Resources Resources for physicians and healthcare professionals including continuing education programs, best practices guidelines, and diagnostic tools for PSP, CBD, and MSA, delivered in partnership with the Parkinson's Foundation and Shirley Ryan AbilityLab.
  • Assistive Devices and Adaptive Equipment Directory Curated list of assistive devices and adaptive equipment recommendations for patients and families dealing with PSP, CBD, and MSA symptoms.
  • CurePSPTV (YouTube Channel) YouTube channel featuring educational and awareness video content about PSP, CBD, and MSA.
  • The Collective Mind Podcast Podcast series featuring stories from care partners, advocates, physicians, scientists, researchers, and staff members discussing PSP, CBD, and MSA. Currently in Season 3 with monthly episodes released on Apple Podcasts, Spotify, Amazon Music, and iHeart.
  • Annual Reports and Financial Statements Annual reports and audited financial statements documenting CurePSP's activities, finances, and impact.

Quantifiable outcome

  • 25 designated Centers of Care providing specialized care for PSP, CBD, and MSA patients across U.S. and Canada
  • +3 more outcomes

Companies that use CurePSP

Customer profile

Named customers15 records

Segments5 records

Ideal customer profiles2 records

CurePSP technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CurePSP partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • PSPA (UK)coreStrategic or Co-development Partner · 1 November 2026Co-organizer of Neuro2026: The PSP and CBD International Research Symposium in London, bringing together the PSP and CBD research community with early clinical trial results expected.
  • Parkinson CanadacoreStrategic or Co-development Partner · 22 June 2026Co-funding partnership for CARES grants supporting research and care initiatives for PSP, CBD, and MSA in Canada. Two projects are co-funded including research on barriers to diagnosis in underserved populations and evaluation of virtual wellness programs.
  • Alzheimer's AssociationcoreStrategic or Co-development Partner · 14 May 2026Co-organizer of Tau Global Conference 2026, bringing together approximately 400 in-person attendees and 800 virtual participants including researchers, clinicians, and people living with PSP, CBD and related tauopathies.
  • Rainwater Charitable FoundationcoreStrategic or Co-development Partner · 14 May 2026Co-organizer of Tau Global Conference 2026 and provider of the Rainwater Prize honoring researchers at the Mayo Clinic Brain Bank. Partnership advancing tau research and awareness.
  • Mayo Clinic Brain BankcoreStrategic or Co-development PartnerHosts CurePSP's Brain Bank with over 2,000 PSP brains of frozen and fixed tissue. Provides neuropathologic evaluation at no charge and generates diagnostic reports for families. Tissue is shared with researchers nationally and internationally.
  • Parkinson's FoundationcoreStrategic or Co-development PartnerPartnership on Atypical Parkinsonism Podcast Series and online course 'Caring for Your Patients with Atypical Parkinsonism' providing continuing education credits for healthcare professionals.
  • Shirley Ryan AbilityLabminorStrategic or Co-development PartnerPartnership on on-demand webinar 'Rehabilitation Implications of Atypical Parkinsonisms' providing continuing education credits for physical therapists, occupational therapists, and speech-language pathologists.
  • CND Life SciencesminorStrategic or Co-development PartnerCorporate supporter of the online course 'Caring for Your Patients with Atypical Parkinsonism' developed in partnership with Parkinson's Foundation.
  • National Parkinson's Project Advisory CouncilcoreOthersJessica Shurer, Director of Clinical Affairs and Advocacy at CurePSP, appointed to the inaugural National Parkinson's Project Advisory Council under the National Plan to End Parkinson's Act. Council will evaluate federal programs, advise HHS Secretary, and deliver recommendations on research priorities and care access strategies.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

CurePSP competitors and assessment

Company assessment

Direct peers

  • Alzheimer's Association: The largest U.S. voluntary health organization for dementia and a core co-organizer of the Tau Global Conference with CurePSP. Shares research funding mechanisms and federal advocacy, with overlapping interest in tau biology linking Alzheimer's and PSP/CBD.
  • Parkinson's Foundation: National Parkinson advocacy and patient-support organization that co-publishes the Atypical Parkinsonism Podcast Series and the 'Caring for Your Patients with Atypical Parkinsonism' continuing-education course with CurePSP. Comparable in mission (care, education, research funding) and audience (Parkinson's and atypical parkinsonism patients and clinicians).
  • ALS Association: Major U.S. voluntary health organization focused on amyotrophic lateral sclerosis with the same three-pillar operating model (care, awareness, research funding) as CurePSP. Comparable scale, federal advocacy footprint, and Care Center network structure make it a structurally similar peer.
  • Association for Frontotemporal Degeneration (AFTD): U.S. nonprofit focused on frontotemporal degeneration, an adjacent rare neurodegenerative disease with a similar patient-support, education, and research-funding operating model. Comparable in scale, structure, and disease-rare-advocacy positioning.
  • Lewy Body Dementia Association: U.S. voluntary health organization for Lewy body dementia, another synucleinopathy adjacent to MSA with overlapping patient populations and a similar support, education, and research-advocacy mission.
  • The Michael J. Fox Foundation for Parkinson's Research: The largest nonprofit funder of Parkinson's research, with a federal advocacy agenda that overlaps CurePSP's on the National Parkinson's Project Advisory Council. MJFF and CurePSP co-publish advocacy calls (e.g., the June 2026 advisory council coalition statement), making MJFF a direct peer in research funding, federal lobbying, and patient education.
  • Rainwater Charitable Foundation: Private foundation focused on tauopathy and neurodegenerative disease research that co-organizes the Tau Global Conference and funds the Rainwater Prize at the Mayo Clinic Brain Bank. Direct peer on CurePSP's most differentiated research asset.
  • Parkinson Canada: Canadian national Parkinson advocacy organization that co-funds CurePSP's CARES grants for Canadian projects. Direct peer in cross-border atypical parkinsonism care and research funding.
  • PSPA (Progressive Supranuclear Palsy Association): The UK-based PSP and CBD patient organization and co-organizer of Neuro2026 with CurePSP. Operates the same disease-specific care, research funding, and awareness model outside North America.
  • American Parkinson Disease Association: National Parkinson's disease nonprofit providing patient services, professional education, and research grants, overlapping CurePSP on the federal Parkinson's advocacy coalition. Operates a comparable support-group and information-resource model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

CurePSP social profiles

Digital presence

CurePSP financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CurePSP leadership team

Management profile

Number of profiles

Profiles4 records

CurePSP funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CurePSP M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CurePSP

What does CurePSP do?

CurePSP is a 501(c)(3) nonprofit organization that raises awareness, funds research, and provides patient and family support services for three rare neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). Its core offerings include educational resources, the Quality of Life Respite Program, the Brain Donation Assistance Program, the Centers of Care Network, and research grant programs (CARES, Pathway, and Pipeline grants).

Is CurePSP a public or private company?

CurePSP is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was CurePSP founded?

CurePSP was founded in 1993.

Where is CurePSP based?

CurePSP is headquartered in New York, United States, in the North America region.

How does CurePSP make money?

One revenue line is on record: donations and Fundraising.

Who are CurePSP's main competitors?

Direct peers on record are Alzheimer's Association, Parkinson's Foundation, ALS Association, Association for Frontotemporal Degeneration (AFTD), Lewy Body Dementia Association, The Michael J. Fox Foundation for Parkinson's Research, Rainwater Charitable Foundation, Parkinson Canada, PSPA (Progressive Supranuclear Palsy Association) and American Parkinson Disease Association.

Does CurePSP have an API?

No public API is recorded for CurePSP.

What industry is CurePSP in?

CurePSP's product category is Neurodegenerative Disease Nonprofit Patient Advocacy. Its primary akta.pro industry code is HLAJAOAD, Public–Private Partnerships (PPPs) for Global Health, with a secondary code of HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 813212 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireCurePSP Establishes Public Policy and Advocacy Team to Accelerate National ImpactCurePSP established its Public Policy and Advocacy team, adding Nora Wong and Julie Balasalle. Wong leads policy and government relations, while Balasalle drives community advocacy. The team aims to shape policies affecting research and care for PSP, CBD, and MSA.GlobeNewswireUPDATE - CurePSP Announces Enrollment of First Participant in the PSP Trial PlatformThe PSP Trial Platform (PTP), a landmark clinical trial for progressive supranuclear palsy led by the University of California, San Francisco and funded by the National Institute on Aging, has enrolled its first participant. The trial aims to enroll 440 participants over two years across 50 sites nationwide to test multiple drugs concurrently, including LM11A-31 from PharmatrophiX and AADvac1 from Axon Neuroscience.GlobeNewswireCurePSP Announces Enrollment of First Participant in the PSP Trial PlatformThe PSP Trial Platform (PTP) has enrolled its first participant in a landmark clinical trial led by the University of California, San Francisco and funded by the National Institute on Aging. The trial aims to enroll 440 participants over two years to test multiple drugs concurrently for progressive supranuclear palsy, including LM11A-31 from PharmatrophiX and AADvac1 from Axon Neuroscience.FinancialContent Business PageCurePSP Announces Enrollment of First Participant in the PSP Trial PlatformThe PSP Trial Platform, a clinical trial testing multiple drugs for PSP, has enrolled its first participant. The trial is conducted at 50 sites nationwide, aiming to expedite development of effective treatments for PSP and possibly advance diagnostics.GlobeNewswireCurePSP Invests in the Next Generation of PSP and CBD Researchers with Student Fellowship AwardsCurePSP announced seven student fellowship recipients under its Urso Student Fellowship Grant (four projects) and Jim Atwood Neuroscience Student Fellowship (three projects), supporting research into progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and related tauopathies. Recipients include undergraduate students, PhD students, and medical trainees who will conduct research at institutions across North America, Europe, and Africa. The organization stated that building a pipeline of researchers focused on these neurodegenerative diseases is vital to sustaining progress toward treatments and cures.FinancialContent Business PageCurePSP Awards Record Pathway and Pipeline Grants to Advance PSP and CBD ResearchCurePSP announced its largest grant cycle to date, awarding a record number of Pathway and Pipeline Grants to researchers across North America and Europe for research into progressive supranuclear palsy, corticobasal degeneration, and related neurodegenerative disorders. The grant portfolio includes a $300,000 contribution from the Rainwater Charitable Foundation and spans diverse scientific approaches including spatial transcriptomics, AI-driven therapeutic design, and genetic risk factor analysis. Awardees are based at institutions including Yale University, University of California Los Angeles, Mayo Clinic Jacksonville, University of Cambridge, University of Texas Southwestern Medical Center, LMU University Hospital, and University College London.GlobeNewswireCurePSP Awards Record Pathway and Pipeline Grants to Advance PSP and CBD ResearchCurePSP announced its largest grant cycle to date, awarding a record number of Pathway and Pipeline Grants to researchers across North America and Europe for progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) research. The grant cycle includes a $300,000 contribution from the Rainwater Charitable Foundation, one of the largest independent funders of primary tauopathy research. Funded projects span diverse scientific approaches including spatial transcriptomics, AI-driven therapeutic design, computer vision biomarker development, and genetic risk factor analysis at institutions such as Yale University, UCLA, Mayo Clinic Jacksonville, University of Cambridge, UT Southwestern, LMU University Hospital, and University College London.AM 1240 WJONRemembering Neal Ditlevson: A Life In St. CloudNeal Ditlevson, a 66-year-old salesman for Alternative Business Furniture, passed away on June 24, 2026, following a diagnosis of Progressive Supranuclear Palsy. His family has arranged for a memorial service at the Joy Christian Center in St. Cloud and requested donations to the Cure PSP Foundation.PR NewswireAhead of First National Parkinson's Project Advisory Council Meeting, Leading Parkinson's Organizations Call for Urgent ActionFour leading Parkinson's disease organizations—the American Parkinson Disease Association, The Michael J. Fox Foundation, the Parkinson's Foundation, and CurePSP—are calling on the newly seated National Parkinson's Project Advisory Council to act urgently ahead of its first meeting on June 29, 2026, urging the body to produce its first report within one year and prioritize research funding estimates. The organizations are advocating for at least $1.5 billion in federal Parkinson's research funding by 2032, noting that the economic burden of Parkinson's disease and atypical parkinsonisms totaled an estimated $82.2 billion in 2024 while current federal investment represents less than 1% of that figure. The groups are also pressing for actionable recommendations to improve access to integrated, high-quality care, noting that fewer than 10% of Parkinson's patients currently receive care from movement disorders specialists.FinancialContent Business PageCurePSP Expands Grant Program with $155,000 Investment in Studying Care for Rare Neurological DiseasesCurePSP announced the latest recipients of its Collaborative Approaches to Resources, Education and Support (CARES) grants, awarding $155,000 to four research projects at seven medical institutions in the U.S. and Canada. The grants focus on progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA), funding initiatives including peer mentorship program development, interdisciplinary care access research, diagnostic barriers studies, and virtual wellness programs. Now in its fourth year, the CARES program requires projects to involve at least two CurePSP Centers of Care and target person-centered care, access, underserved populations, or medical education.